EP1366044B1 - 8-{4-[3-(5-fluoro-1h-indol-3-yl)propyl] -1-piperazinyl} -2-methyl-2h-1, 4-benzoxazin-3(4h)-on methanesulfonat mit hoher affinität für den dopamin d2 rezeptor und den serotonin reuptake site - Google Patents

8-{4-[3-(5-fluoro-1h-indol-3-yl)propyl] -1-piperazinyl} -2-methyl-2h-1, 4-benzoxazin-3(4h)-on methanesulfonat mit hoher affinität für den dopamin d2 rezeptor und den serotonin reuptake site Download PDF

Info

Publication number
EP1366044B1
EP1366044B1 EP02719880A EP02719880A EP1366044B1 EP 1366044 B1 EP1366044 B1 EP 1366044B1 EP 02719880 A EP02719880 A EP 02719880A EP 02719880 A EP02719880 A EP 02719880A EP 1366044 B1 EP1366044 B1 EP 1366044B1
Authority
EP
European Patent Office
Prior art keywords
dopamine
receptor
serotonin reuptake
benzoxazin
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP02719880A
Other languages
English (en)
French (fr)
Other versions
EP1366044A1 (de
Inventor
Cornelis Bakker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Healthcare Products BV
Original Assignee
Abbott Healthcare Products BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Healthcare Products BV filed Critical Abbott Healthcare Products BV
Priority to EP02719880A priority Critical patent/EP1366044B1/de
Publication of EP1366044A1 publication Critical patent/EP1366044A1/de
Application granted granted Critical
Publication of EP1366044B1 publication Critical patent/EP1366044B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention relates to the novel phenylpiperazine derivative of the formula (I):
  • Patent application WO 01/14330 A relates a group of novel phenyl piperazines.
  • the compounds of that group show high affinity for both the dopamine D 2 receptor and the serotonin reuptake site. This combination is useful for the treatment of schizophrenia and other psychotic disorders which enables a more complete treatment of all disease symptoms (e.g. positive symptoms and negative symptoms).
  • the compounds show activity as antagonists at dopamine D 2 receptors as they potentially antagonize apomorphine-induced climbing behaviour in mice.
  • the compounds also show activity as inhibitors of serotonin reuptake, as they potentiate 5-HTP induced behaviour in mice.
  • the compounds are active in therapeutic models sensitive to clinically relevant antipsychotics (e.g. the conditioned avoidance response; Van der Heyden & Bradford, Behav. Brain Res., 1988, 31:61-67 ) and antidepressants or anxiolytics (e.g. suppression of stress-induced vocalization; van der Poel et al., Psychopharmacology, 1989, 97: 147-148 ).
  • clinically relevant antipsychotics e.g. the conditioned avoidance response; Van der Heyden & Bradford, Behav. Brain Res., 1988, 31:61-67
  • antidepressants or anxiolytics e.g. suppression of stress-induced vocalization; van der Poel et al., Psychopharmacology, 1989, 97: 147-148 .
  • the described compounds In contrast to clinically relevant dopamine D 2 receptor antagonists the described compounds have a low propensity to induce catalepsy in rodents and as such are likely to induce less extrapyramidal side effects than existing antipsychotic agents.
  • the inhibitory activity of serotonin reuptake inherent in these compounds may be responsible for the therapeutic effects observed in behavioural models sensitive to either antidepressants or anxiolytics.
  • the compounds can be used for the treatment of affections or diseases of the central nervous system caused by disturbances in either the dopaminergic or serotonergic systems, for example: aggression, anxiety disorders, autism, vertigo, depression, disturbances of cognition or memory, Parkinson's disease, and in particular schizophrenia and other psychotic disorders.
  • This mesylate compound is much better soluable in water than the free base resulting in a good bio- availability.
  • the compound has a centre of chirality; both the racemic mixture and the individual enantiomers belong to the invention.
  • the compound can be brought into forms suitable for administration by means of suitable processes using auxiliary substances such as liquid and solid carrier materials.
  • the free base of compounds can be prepared as described in EP 99202710.2
  • the free base can be converted into the mesylate according to processes known per se for salt formation.
  • the invention is illustrated by means of the following Example.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (3)

  1. Verbindung der Formel
    Figure imgb0003
  2. Pharmazeutische Zusammensetzung zum Behandeln von Störungen des ZNS, dadurch gekennzeichnet, dass sie die Verbindung nach Anspruch 1 als Wirkstoff enthält.
  3. Verwendung der Verbindung nach Anspruch 1 für die Herstellung eines Medikaments zur Behandlung von Störungen des ZNS.
EP02719880A 2001-02-21 2002-02-19 8-{4-[3-(5-fluoro-1h-indol-3-yl)propyl] -1-piperazinyl} -2-methyl-2h-1, 4-benzoxazin-3(4h)-on methanesulfonat mit hoher affinität für den dopamin d2 rezeptor und den serotonin reuptake site Expired - Lifetime EP1366044B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP02719880A EP1366044B1 (de) 2001-02-21 2002-02-19 8-{4-[3-(5-fluoro-1h-indol-3-yl)propyl] -1-piperazinyl} -2-methyl-2h-1, 4-benzoxazin-3(4h)-on methanesulfonat mit hoher affinität für den dopamin d2 rezeptor und den serotonin reuptake site

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01200610 2001-02-21
EP01200610 2001-02-21
PCT/EP2002/001795 WO2002066473A1 (en) 2001-02-21 2002-02-19 8’4-’3-(5-fluoro-1h-indol-3yl) propyl!-1-piperazynyl!-2-methyl-2h-1,4-benzoxazin -3 (4h)- one methanesulfonate with high affinity for the dopamine d 2 receptor and the serotonin reuptake site
EP02719880A EP1366044B1 (de) 2001-02-21 2002-02-19 8-{4-[3-(5-fluoro-1h-indol-3-yl)propyl] -1-piperazinyl} -2-methyl-2h-1, 4-benzoxazin-3(4h)-on methanesulfonat mit hoher affinität für den dopamin d2 rezeptor und den serotonin reuptake site

Publications (2)

Publication Number Publication Date
EP1366044A1 EP1366044A1 (de) 2003-12-03
EP1366044B1 true EP1366044B1 (de) 2010-06-30

Family

ID=8179909

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02719880A Expired - Lifetime EP1366044B1 (de) 2001-02-21 2002-02-19 8-{4-[3-(5-fluoro-1h-indol-3-yl)propyl] -1-piperazinyl} -2-methyl-2h-1, 4-benzoxazin-3(4h)-on methanesulfonat mit hoher affinität für den dopamin d2 rezeptor und den serotonin reuptake site

Country Status (25)

Country Link
US (2) US6958396B2 (de)
EP (1) EP1366044B1 (de)
JP (1) JP4216072B2 (de)
KR (1) KR100859107B1 (de)
CN (1) CN1284780C (de)
AR (1) AR032712A1 (de)
AT (1) ATE472545T1 (de)
AU (1) AU2002250983B2 (de)
BR (1) BR0206162A (de)
CA (1) CA2430707C (de)
CZ (1) CZ20032171A3 (de)
DE (1) DE60236848D1 (de)
DZ (1) DZ3490A1 (de)
ES (1) ES2347321T3 (de)
HK (1) HK1078569A1 (de)
HU (1) HUP0303330A3 (de)
IL (1) IL155720A0 (de)
MX (1) MXPA03007430A (de)
NO (1) NO325298B1 (de)
NZ (1) NZ526018A (de)
PL (1) PL201176B1 (de)
RU (1) RU2281945C2 (de)
SK (1) SK10412003A3 (de)
WO (1) WO2002066473A1 (de)
ZA (1) ZA200304267B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4919565B2 (ja) * 1999-08-23 2012-04-18 アボツト・ヘルスケア・プロダクツ・ベー・ブイ 新規なフェニルピペラジン
AR032712A1 (es) * 2001-02-21 2003-11-19 Solvay Pharm Bv Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen
US7371769B2 (en) 2004-12-07 2008-05-13 Solvay Pharmaceuticals B.V. Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
CA2587928A1 (en) * 2004-12-07 2006-06-15 Solvay Pharmaceuticals B.V. Phenylpiperazines with a combination of affinity for dopamine -d2 receptors and serotonin reuptake sites
US20070072870A2 (en) 2004-12-08 2007-03-29 Solvay Pharmeceuticals B.V. Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition
AR055424A1 (es) * 2005-09-12 2007-08-22 Wyeth Corp Formulacion de liberacion sostenida y usos de la misma
GT200600416A (es) * 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
GT200600414A (es) * 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1075156A (en) 1963-08-27 1967-07-12 Luso Farmaco Inst Substituted piperazines
SE381564B (sv) * 1973-03-19 1975-12-15 Stiftelsen Teknisk Hjelp At Ha Eldriven rullstol
US4018440A (en) * 1975-03-31 1977-04-19 Deutsch Fritz A Invalid walker with wheel control mechanism
US4076270A (en) * 1976-01-19 1978-02-28 General Motors Corporation Foldable cambering vehicle
US4088199A (en) * 1976-02-23 1978-05-09 Wolfgang Trautwein Stabilized three-wheeled vehicle
BE841212A (nl) * 1976-04-28 1976-08-16 Sportvoertuig
US4062558A (en) * 1976-07-19 1977-12-13 David Wasserman Unicycle
US4094372A (en) * 1977-02-28 1978-06-13 Notter Michael A Motorized skateboard with uni-directional rear mounting
US4111445A (en) * 1977-06-09 1978-09-05 Kenneth Haibeck Device for supporting a paraplegic in an upright position
US4109741A (en) * 1977-07-29 1978-08-29 Gabriel Charles L Motorized unicycle wheel
DE2807517C3 (de) * 1978-02-22 1980-12-04 Habegger, Willy, Huenibach Bei Thun (Schweiz) Fahr- und Schreitwerk für Fahrzeuge, insbesondere fahrbare Krane, Bagger u.dgl
US4222449A (en) * 1978-06-08 1980-09-16 Feliz Jack M Step-climbing wheel chair
US4293052A (en) * 1978-07-17 1981-10-06 Daswick Alexander C Lightweight two-wheeled vehicle
US4264082A (en) * 1979-03-26 1981-04-28 Fouchey Jr Charles J Stair climbing cart
DE2915387A1 (de) * 1979-04-14 1980-10-16 Heinz Eichholz Elektrofahrzeug
US4325565A (en) * 1980-03-03 1982-04-20 General Motors Corporation Cambering vehicle
US4373600A (en) * 1980-07-18 1983-02-15 Veda, Inc. Three wheel drive vehicle
US4363493A (en) * 1980-08-29 1982-12-14 Veneklasen Paul S Uni-wheel skate
US4740001A (en) * 1981-09-14 1988-04-26 Torleumke Keith R Sprag wheel
US4375840A (en) * 1981-09-23 1983-03-08 Campbell Jack L Mobile support
US4566707A (en) * 1981-11-05 1986-01-28 Nitzberg Leonard R Wheel chair
US4570078A (en) * 1982-05-27 1986-02-11 Honda Giken Kogyo Kabushiki Kaisha Switch assembly for a motor vehicle
GB2121961B (en) * 1982-06-09 1985-10-02 Jeco Kk Angle change detector
JPS6025302U (ja) * 1983-07-22 1985-02-21 アツプリカ葛西株式会社 電動式子供用乗物
US4510956A (en) * 1983-08-15 1985-04-16 Lorraine King Walking aid, particularly for handicapped persons
FR2576863A1 (fr) * 1985-01-31 1986-08-08 Brunet Pierre Dispositif de deplacement motorise, par exemple pour monter et descendre des escaliers
GB8515992D0 (en) * 1985-06-25 1985-07-31 Hester R Wheelchair
US4657272A (en) * 1985-09-11 1987-04-14 Davenport James M Wheeled vehicle
US4624469A (en) * 1985-12-19 1986-11-25 Bourne Jr Maurice W Three-wheeled vehicle with controlled wheel and body lean
JPH0412977Y2 (de) * 1986-01-28 1992-03-27
US4716980A (en) * 1986-02-14 1988-01-05 The Prime Mover Company Control system for rider vehicles
US4786069A (en) * 1986-06-30 1988-11-22 Tang Chun Yi Unicycle
US4770410A (en) * 1986-07-03 1988-09-13 Brown Guies L Walker
GB8618044D0 (en) * 1986-07-24 1986-09-03 Sheeter E Vehicle
WO1988000899A1 (en) * 1986-07-28 1988-02-11 Arthur George Yarrington Heli-hover amphibious surface effect vehicle
US4809804A (en) * 1986-08-25 1989-03-07 Falcon Rehabilitation Products, Inc. Combination wheelchair and walker apparatus
US4802542A (en) * 1986-08-25 1989-02-07 Falcon Rehabilitation Products, Inc. Powered walker
US4685693A (en) * 1986-09-16 1987-08-11 Vadjunec Carl F Upright wheelchair
JPS63150176A (ja) * 1986-12-15 1988-06-22 工業技術院長 動的歩行ロボツトの歩行制御方法
US4869279A (en) * 1986-12-22 1989-09-26 Hedges Harry S Walker
US4746132A (en) * 1987-02-06 1988-05-24 Eagan Robert W Multi-wheeled cycle
CA1275296C (en) * 1987-05-04 1990-10-16 Pierre Decelles Climbing and descending vehicle
US4798255A (en) * 1987-10-29 1989-01-17 Wu Donald P H Four-wheeled T-handlebar invalid carriage
US4874055A (en) * 1987-12-16 1989-10-17 Beer Robin F C Chariot type golf cart
US4890853A (en) * 1988-03-07 1990-01-02 Luanne Olson Wheelchair walker
US4919225A (en) * 1988-03-31 1990-04-24 Sturges Daniel D Platform oriented transportation vehicle
US4863182A (en) * 1988-07-21 1989-09-05 Chern Jiuun F Skate bike
US4953851A (en) * 1988-11-07 1990-09-04 Sherlock Lila A Safety mobilizer walker
GB8830312D0 (en) * 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
US4998596A (en) * 1989-05-03 1991-03-12 Ufi, Inc. Self-propelled balancing three-wheeled vehicle
DE69018508D1 (de) * 1989-05-17 1995-05-18 Aluweld Sa Antriebseinrichtung.
CH681353A5 (de) * 1989-05-17 1993-03-15 Aluweld Sa
US5248007A (en) * 1989-11-21 1993-09-28 Quest Technologies, Inc. Electronic control system for stair climbing vehicle
US5002295A (en) * 1990-04-19 1991-03-26 Pro-China Sporting Goods Industries Inc. Unicycle having an eccentric wheel
US5011171A (en) * 1990-04-20 1991-04-30 Cook Walter R Self-propelled vehicle
US4985947A (en) * 1990-05-14 1991-01-22 Ethridge Kenneth L Patient assist device
DE4016610A1 (de) * 1990-05-23 1991-11-28 Audi Ag Sicherheitseinrichtung an einem kraftfahrzeug mit einem aufblasbaren gaskissen
US5171173A (en) * 1990-07-24 1992-12-15 Zebco Corporation Trolling motor steering and speed control
DE4030119A1 (de) * 1990-09-24 1992-03-26 Uwe Kochanneck Multiblock-robot
DE4134831C2 (de) * 1991-10-22 1995-05-18 Mannesmann Ag Anordnung zur Ermittlung einer Reibbeiwert-Information
EP0488693B1 (de) * 1990-11-30 1997-01-29 Honda Giken Kogyo Kabushiki Kaisha System zur Steuerung der Fortbewegung eines Schreitroboters mit Beinen
JP3280392B2 (ja) * 1991-04-01 2002-05-13 アイシン・エィ・ダブリュ株式会社 電動車両の駆動力制御装置
US5168947A (en) * 1991-04-09 1992-12-08 Rodenborn Eugene P Motorized walker
US5158493A (en) * 1991-05-30 1992-10-27 Richard Morgrey Remote controlled, multi-legged, walking robot
DE4127849A1 (de) 1991-08-22 1993-02-25 Merck Patent Gmbh Benzodioxanderivate
US5186270A (en) * 1991-10-24 1993-02-16 Massachusetts Institute Of Technology Omnidirectional vehicle
US5314034A (en) * 1991-11-14 1994-05-24 Chittal Nandan R Powered monocycle
US5314896A (en) 1991-11-20 1994-05-24 Warner-Lambert Company 1,3-substituted cycloalkenes and cycloalkanes as central nervous system agents
US5366036A (en) * 1993-01-21 1994-11-22 Perry Dale E Power stand-up and reclining wheelchair
US5971091A (en) * 1993-02-24 1999-10-26 Deka Products Limited Partnership Transportation vehicles and methods
US5701965A (en) * 1993-02-24 1997-12-30 Deka Products Limited Partnership Human transporter
US5975225A (en) * 1993-02-24 1999-11-02 Deka Products Limited Partnership Transportation vehicles with stability enhancement using CG modification
US5350033A (en) * 1993-04-26 1994-09-27 Kraft Brett W Robotic inspection vehicle
JPH0787602A (ja) * 1993-09-17 1995-03-31 Matsushita Electric Ind Co Ltd 電気自動車の保護装置
DE4333254A1 (de) 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
DE4414113A1 (de) 1994-04-22 1995-10-26 Merck Patent Gmbh 3-Indolylpiperidine
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5701968A (en) * 1995-04-03 1997-12-30 Licile Salter Packard Children's Hospital At Stanford Transitional power mobility aid for physically challenged children
US6059062A (en) * 1995-05-31 2000-05-09 Empower Corporation Powered roller skates
US6050357A (en) * 1995-05-31 2000-04-18 Empower Corporation Powered skateboard
US6003624A (en) * 1995-06-06 1999-12-21 University Of Washington Stabilizing wheeled passenger carrier capable of traversing stairs
AR004229A1 (es) 1995-11-06 1998-11-04 Wyeth Corp Derivados indolalquilo de benzodioxanmetilamina y su uso para preparar medicamentos
US5775452A (en) * 1996-01-31 1998-07-07 Patmont Motor Werks Electric scooter
DE19625498C1 (de) * 1996-06-26 1997-11-20 Daimler Benz Ag Bedienelementanordnung zur Steuerung der Längs- und Querbewegung eines Kraftfahrzeuges
JP3451848B2 (ja) * 1996-09-10 2003-09-29 トヨタ自動車株式会社 電気自動車の駆動制御装置
US5986221A (en) * 1996-12-19 1999-11-16 Automotive Systems Laboratory, Inc. Membrane seat weight sensor
ZA9711376B (en) * 1996-12-20 1998-07-21 Lundbeck & Co As H Indole or dihydroindole derivatives
US6225977B1 (en) * 1997-03-25 2001-05-01 John Li Human balance driven joystick
DE19730989A1 (de) * 1997-07-18 1999-01-21 Merck Patent Gmbh Piperazin-Derivate
WO1999005140A1 (en) 1997-07-25 1999-02-04 H. Lundbeck A/S Indole and 2,3-dihydroindole derivatives, their preparation and use
ATE253058T1 (de) * 1997-09-02 2003-11-15 Duphar Int Res Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten
US6125957A (en) * 1998-02-10 2000-10-03 Kauffmann; Ricardo M. Prosthetic apparatus for supporting a user in sitting or standing positions
CA2335711A1 (en) 1998-06-19 1999-12-29 Ivan Mikkelsen 4,5,6 and 7-indole and indoline derivatives, their preparation and use
AR020773A1 (es) * 1998-10-16 2002-05-29 Duphar Int Res Compuesto derivados de 3-(tetrahidropiridin-4-il)indol, metodo para prepararlo, una composicion farmaceutica que los contiene, metodo para preparar dicha composicion y uso del compuesto
US6223104B1 (en) * 1998-10-21 2001-04-24 Deka Products Limited Partnership Fault tolerant architecture for a personal vehicle
US6302230B1 (en) * 1999-06-04 2001-10-16 Deka Products Limited Partnership Personal mobility vehicles and methods
US6314896B1 (en) 1999-06-10 2001-11-13 L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Method for operating a boiler using oxygen-enriched oxidants
JP4919565B2 (ja) * 1999-08-23 2012-04-18 アボツト・ヘルスケア・プロダクツ・ベー・ブイ 新規なフェニルピペラジン
US6288505B1 (en) * 2000-10-13 2001-09-11 Deka Products Limited Partnership Motor amplifier and control for a personal transporter
AR032711A1 (es) 2001-02-21 2003-11-19 Solvay Pharm Bv Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene
AR032712A1 (es) * 2001-02-21 2003-11-19 Solvay Pharm Bv Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen
EP1336406A1 (de) 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Partieller Dopamin-D2 Rezeptoragonist plus Substanzen mit Serotonin- und/oder Noradrenalin inhibitorischer Aktivität

Also Published As

Publication number Publication date
HUP0303330A2 (en) 2006-02-28
US20040024207A1 (en) 2004-02-05
CN1639156A (zh) 2005-07-13
IL155720A0 (en) 2003-11-23
RU2281945C2 (ru) 2006-08-20
KR100859107B1 (ko) 2008-09-18
HK1078569A1 (en) 2006-03-17
CA2430707C (en) 2011-04-26
US8106044B2 (en) 2012-01-31
NO20032914L (no) 2003-06-24
DZ3490A1 (fr) 2002-08-29
WO2002066473A8 (en) 2004-01-29
PL362288A1 (en) 2004-10-18
SK10412003A3 (sk) 2004-03-02
NZ526018A (en) 2005-03-24
CZ20032171A3 (cs) 2003-11-12
AR032712A1 (es) 2003-11-19
ZA200304267B (en) 2004-08-30
KR20030072633A (ko) 2003-09-15
BR0206162A (pt) 2003-10-28
EP1366044A1 (de) 2003-12-03
ES2347321T3 (es) 2010-10-28
PL201176B1 (pl) 2009-03-31
US6958396B2 (en) 2005-10-25
DE60236848D1 (de) 2010-08-12
HUP0303330A3 (en) 2009-10-28
MXPA03007430A (es) 2003-11-18
NO325298B1 (no) 2008-03-17
US20050209228A1 (en) 2005-09-22
ATE472545T1 (de) 2010-07-15
CN1284780C (zh) 2006-11-15
CA2430707A1 (en) 2002-08-29
WO2002066473A1 (en) 2002-08-29
JP2004518747A (ja) 2004-06-24
JP4216072B2 (ja) 2009-01-28
NO20032914D0 (no) 2003-06-24
AU2002250983B2 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
US20050209228A1 (en) 8-{4-[3-(5-fluoro-1H-indol-3-yl)-propyl]-piperazin-1-yl}-2-methyl-4H-benzo[1,4]oxazin-3-one mesylate with high affinity for the dopamine D2 receptor and the serotonin reuptake site
US7605162B2 (en) Phenylpiperazine
JP2007509140A (ja) ５−ＨＴ６受容体に関連する疾患の処置において有用な新規テトラヒドロスピロ｛ピペリジン−２，７’−ピロロ［３，２−ｂ］ピリジン誘導体および新規インドール誘導体
JP2003524571A (ja) インドール−及び２，３−ジヒドロインドール誘導体、その製造方法及びその使用方法
JP2008543782A (ja) ５−ｈｔ１ａ受容体のピペラジン−ピペリジンアンタゴニストおよびアゴニスト
EA006604B1 (ru) Сочетание агониста (5-ht2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции
AU2002237654A1 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders
AU2002250983A1 (en) 8-{4-[3-(5-fluoro-1H-indol-3-yl)-propyl]-piperazin-1-yl}-2-methyl-4H-benzo[1,4]oxazin-3-one mesylate with high affinity for the dopamine D2 receptor and the serotonin reuptake site
EP1824486B1 (de) Bezdioxan-piperazin-derivate mit einer kombination aus affinität für dopamin-d2-rezeptoren und serotonin-wiederaufnahme-stellen
CN101641350A (zh) 二苯并[b,f][1,4]氧杂氮杂䓬化合物
JP2004512364A (ja) 中枢神経系疾患の治療のためのスルホンアミド
AU2005313386A1 (en) Phenylpiperazines with a combination of affinity for dopamine -D2 receptors and serotonin reuptake sites
JPH09504272A (ja) ドーパミンアンタゴニストとしてのイミダゾロン及びオキサゾロン誘導体
MXPA01012449A (es) Derivados de acilaminciclopropano.
WO2008084324A1 (en) Naphthyridinone compound
US7371769B2 (en) Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
AU2005313387A1 (en) Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
UA74055C2 (en) 8-{4-[3-(5-fluoro-1??-indol-3-yl)propyl]-piperazine-1-yl}-2-methyl-4??-benzo[1,4]oxazine-3-??n mesylate with a high affinity to receptor of dopamine d2 and site of repetitive assimilation of serotonin, a pharmaceutical composition and a method for the treatment of cns disorders
CZ2000947A3 (cs) Substituované chromanové deriváty

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17P Request for examination filed

Effective date: 20030509

RTI1 Title (correction)

Free format text: 8-??4-??3-(5-FLUORO-1H-INDOL-3-YL)PROPYL -1-PIPERAZINYL -2-METHYL-2H-1, 4-BENZOXAZIN-3(4H)-ONE METHANESULFONATE WITH HIGH AFFINITY FOR THE DOPAMINE D2 RECEPTOR AND THE SEROTONIN

17Q First examination report despatched

Effective date: 20090715

RTI1 Title (correction)

Free format text: 8-(4-(3-(5-FLUORO-1H-INDOL-3-YL)PROPYL )-1-PIPERAZINYL) -2-METHYL-2H-1, 4-BENZOXAZIN-3(4H)-ONE METHANESULFONATE WITH HIGH AFFINITY FOR THE DOPAMINE D2 RECEPTOR AND THE SEROTONIN

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABBOTT HEALTHCARE PRODUCTS B.V.

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: LT LV RO SI

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60236848

Country of ref document: DE

Date of ref document: 20100812

Kind code of ref document: P

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER & PEDRAZZINI AG

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2347321

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100630

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20100630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100630

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100630

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100630

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20110223

Year of fee payment: 10

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20110224

Year of fee payment: 10

Ref country code: FR

Payment date: 20110309

Year of fee payment: 10

Ref country code: NL

Payment date: 20110228

Year of fee payment: 10

Ref country code: CH

Payment date: 20110223

Year of fee payment: 10

Ref country code: DE

Payment date: 20110225

Year of fee payment: 10

Ref country code: TR

Payment date: 20110209

Year of fee payment: 10

26N No opposition filed

Effective date: 20110331

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60236848

Country of ref document: DE

Effective date: 20110330

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20110223

Year of fee payment: 10

Ref country code: ES

Payment date: 20110224

Year of fee payment: 10

Ref country code: BE

Payment date: 20110224

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110228

BERE Be: lapsed

Owner name: ABBOTT HEALTHCARE PRODUCTS B.V.

Effective date: 20120228

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20120901

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20120219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120229

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120229

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20121031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120219

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60236848

Country of ref document: DE

Effective date: 20120901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120219

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120229

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120219

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120901

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20130709

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120219